Several studies have shown significant benefits of anti-EGFR agents in various types of solid tumors, such as head and neck cancer, NSCLC, and colorectal and pancreatic cancers, in terms of overall survival, progression-free survival, and overall response rate (Giaccone et al., 2004; Bareschino et al., 2007; Rocha-Lima et al., 2007; Petrelli and Barni, 2011; Petrelli et al., 2011). Here, EGFR is linked to non-small cell lung carcinoma.